- Our Company
- News & Events
- Contact Us
November marks the beginning of Lung Cancer Awareness Month. As lung cancer is the second-most frequently diagnosed cancer worldwide, there is a tremendous amount of on-going clinical research to mitigate lung cancer and one recently completed study was on the “Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea” – https://lnkd.in/gfUQ7YTG.
The aim of this study was to determine the feasibility of cell-free DNA or cfDNA-based next generation sequencing (NGS) using the Guardant360® liquid biopsy test to identify actionable gene alterations in patients with advanced non-small cell lung cancer (aNSCLC). This single-centre non-interventional retrospective study evaluated 405 Korean patients with biopsy-confirmed stage III/IV non-squamous aNSCLC. Tissue biopsy samples were collected at baseline, and/or at progression and analysed with Standard of Care (SOC) testing and cfDNA was also analysed by NGS in some patients concurrently.
The findings of this study showed that the results of cfDNA NGS are highly concordant with those of tissue SOC testing in aNSCLC patients. Plasma analysis identified actionable alterations that were missed or not evaluated by tissue testing, enabling the initiation of targeted therapy. Results from this study add to the body of evidence in the support routine use of cfDNA NGS for patients with aNSCLC. Speak to your doctor today about comprehensive genomic testing with a simple blood draw.
Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.
Reference: Ahn BC, Lee S, Lee J, et al. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea. Cancer Treat Res Commun. 2023;36:100715. doi:10.1016/j.ctarc.2023.100715
#guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #lungcancerawarenessmonth #lungcancer #aNSCLC #NSCLC #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists